Brief: Arcutis And Sato Announce Strategic Collaboration And Licensing Agreement For Topical Roflumilast In Japan
28/02/2024 22:35
Arcutis Biotherapeutics Inc ARQT.O :
* ARCUTIS AND SATO ANNOUNCE STRATEGIC COLLABORATION AND
LICENSING
AGREEMENT FOR TOPICAL ROFLUMILAST IN JAPAN
* ARCUTIS BIOTHERAPEUTICS INC - UNDER TERMS OF AGREEMENT,
ARCUTIS
WILL RECEIVE AN UPFRONT PAYMENT OF $25 MILLION
Source text for Eikon: ID:nGNX5p5fNz
Further company coverage: ARQT.O
Recent news on Arcutis Biotherapeutics
See all newsBrief: Arcutis Biotherapeutics reports inducement grants under Nasdaq listing rule 5635(C)(4
Arcutis Q1 product revenue rises 65% yr/yr, net loss narrows
Brief: Arcutis Announces Promotion Of MAS Matsuda To Executive Vice President And Chief Legal Officer To Support Next Phase Of Growth
Brief: Arcutis Begins Enrolling Phase 1A/1B Study Evaluating Arq-234, A Cd200r Agonist, In Healthy Volunteers And Adults With Atopic Dermatitis
Brief: Arcutis Biotherapeutics Inc Files For Mixed Shelf